ACR 2026 RheumNow Fibromyalgia Topic Compilation c Save
Nociplastic Pain in axSpA
Myositis Hurts
Transcription
This is an ACR twenty twenty six podcast coming to you from ACR in Orlando. Hope you enjoy it. Great rheumatologists go to great meetings like this. RoomNow live twenty twenty seven is happening January 3031 in Dallas, Texas. Join your colleagues from across the country and around the world for an interactive, engaging, and practice changing event.
Go to rheumnow.live to see the full program and register today.
Hello. I'm Anthony Chan reporting for RheumNow here at ACR twenty six in Orlando. And one of the areas that have been studied quite a lot in this meeting is the whole area of nosyplastic pain, where the pain can be coming from conditions such as fibromyalgia, particularly in the area of XBA. And today, there was a nice abstract one three three seven, which was presented here. And I'm together with, Mohamed Bitta from Oregon who actually was presenting this today.
So, Mohamed, very nice welcome to, the room now.
Thank you so much for having me.
Tell us a little bit about this study which you presented today where you assessed nocciplastic pain in EXPA.
Definitely, thank you. So one of the biggest challenges of Axospondyloarthritis is how to phenotype pain. You know, we have different phenotypes, nociceptive which is stemming from active inflammation, neuropathic and nocciplastic. Nocciplastic tend to be the trickiest part because there's pain coming from altered CNS processing and we cannot identify active inflammation or a threat to the tissue. And this is of course the prototype of it is fibromyalgia, but this is very common in patients with exospondyloarthritis up to fifty percent in some studies they end up having nociclastic pain features.
The answer is not to cycle biologics or further intensify the immune system. The answer is to try to quantify, objectify this nociclastic pain and to target that in order to modulate pain and to get patients to a better outcome. So what we did in this study, first we tried to phenotype pain, we get patients, we then do questionnaires, fibromyalgia survey questionnaires ask us, we also try to look at objective evidence of inflammation by doing sacroiliac joint MRIs, by doing CRP levels, and then these patients will undergo what we call quantitative sensory testing. As you know now in the clinic we ask patients rate on a scale from zero to 10 your pain scale. This is very non specific, I personally do not know how to answer this question.
What we're trying to do from this quantitative sensory testing is to try to get an objective number that can maybe help differentiate between different pain phenotypes. So we did three different techniques, one is pressure thresholds. Using an algo meter we apply pressure to specific points in the body, whether it's a joint or it's a non joint area, and whenever patients start feeling pain it will give us a threshold, it's a number. And we are doing other types of techniques such as temporal summation, when we have a neuropen we do repetitive pricks on the trapezius muscle which is a non articular site also to see at the end of that test what would be the number. We think that this is much more objective than asking a scale from zero to 10 and the very interesting finding that we have is that these quantitative sensory testing in specific the pressure thresholds was able to differentiate between patients who have nociplastic pain features versus not and how we define that, we define that based on a cutoff on the fibromyalgia survey questionnaire, because if you're starting with this patient population that we phenotyped nicely, they do not have active inflammation on MRIs or lab work, and then you're having a score that's giving them like widespread pain symptoms and then correlated very nicely with pressure thresholds on the quantitative sensory testing, this reflects the pain phenotype that we're trying to study and we are hoping that we can probably implement this in the future if possible to be able to measure pain in a more objective way.
If we can prove in the future that by employing these type of quantitative sensory testing early on in the patient journey, maybe we might be able to predict who will develop what type of pain and then we can target their pain based on that. Of course there's a lot more things to do but we're starting with the first step right
now. Thanks very much, that seems a very comprehensive study that you presented. Are there people who can have both? Can they be nociceptive and nociceptive at the same time? In other words, these tests can be positive but the MRI can also be positive.
Definitely, this is a very important question and yes, we can have patients who have both phenotypes, nociceptive and nociceptive. Of course, the beginning, at this point in time in 2026, it's not possible really to know which one is the predominant phenotype until we target the inflammation. Our approach is first we target the inflammatory component after some period of time, usually up to six months, where we give the anti inflammatory medication a good amount of time to work, at that point we reassess. If we are seeing any active inflammation, we cannot label it as nociceptive because we might still have nociceptive. But if the nociceptive component is gone, at that point we are more confident that we are dealing with nociceplastic pain features.
Okay, very nice. So I think the message is that it's possible to have one or both in these patients and these tools will help us to classify them a bit better.
Definitely, that's correct.
So thank you very much for that very nice abstract today. I'm Anthony Chan presenting here for RheumNow in Orlando at ACR twenty twenty
six. Thank you.
Hello, and welcome to ACR convergence coverage here on RheumNow. I'm Eric Dine from Summit, New Jersey. I'm joined by doctor Sagan from from Rush, myositis division. And I'm here today to talk to you about abstract 2825. Tell me a little bit about your study.
So again, I'm Deidam Sagan. I'm a myositis clinician researcher from Rush. And in the study, we have conducted an electronic survey, cross sectional survey study, where patients with myositis, about five fifty two patients with myositis who report pain attributable to myositis responded to the survey, and our goal was to understand the characteristics of pain in these patients. So pain was just thought to be not actually prominent in myositis. It's just the, it was long believed to be a painless disease.
So this is really, I guess, taking that step forward, like saying that this is common and now we're trying to understand the characteristics of pain in these people.
And so when you're studying for the boards, usually will say painless disorder. How many of these patients did you find have pain?
Yes. So in several different studies that we've done, approximately seventy percent of patients with myositis report pain that's significant enough to interfere with their daily activities. In some cohort, this number goes up to eighty six percent, and in some of them, it is lower, about sixty five percent, but in general, it seems like majority of the patients with myositis report pain.
And so tell me about how did you find the patients for the study and how did you ask them questions?
Yeah, so this was an electronic survey and we've collaborated with two patient organizations to distribute the survey. And one was the TMA, the Myositis Association, that's the largest patient organization, as well as the MSU, the Myositis Support and Understanding Group. They have their listservs, they have several social media platforms that they actively use, and they've advertised and circulated our survey on these platforms.
And were you able to get a little bit more information about the type of pain, how they describe this pain in Yes,
yes. So that was our goal. So we asked the patients, you know, first of all, we said, do you feel this more in the morning, more in the evening? How does it change during the day? We saw that that was quite variable, and some people reported being worse in the morning, some in the evening, some it's about the same.
So that was one diurnal variation that we've asked people. And then also we asked people, you know, is this a pain that kind of comes and goes or is it a persistent? And majority, over seventy percent of patients said this is a persistent pain that's there all the time.
Was there a difference between myositis subgroups?
Yeah, that is a good question because, so overlap myositis, the patients with myositis who also meets criteria for other autoimmune diseases had the highest levels of pain, and patients with inclusion body myositis had the lowest levels of pain. One
of the things I found interesting about your study was that you had not just, you had quantitative and qualitative information and patients were able to provide you really detailed information. Tell me a little bit about how you're able to understand that qualitative information.
Yeah, so we had two questions in the survey where we asked the patients with a free text question, how do you know that this pain is coming from your myositis and not from something else? So that was one free text question because we really did not wanna give them choices and bias them in any way. It's a new concept and we wanted to learn as much as we can. And then the other question we asked was what makes your pain better and what makes your pain worse in your opinion? So the way we analyze this data, initially, we really didn't expect to get this many responses to our survey.
So we were gonna do a qualitative analysis. But given that we had over 500 responses and all of them had the answers to this free text question, We use actually large language models, the CHECH GPT, and we ask to create themes as well as representative quotes from each theme as an answer to that question. So this is an exploratory approach, obviously, but I think it's gonna be developed and used more and more commonly in the rheumatology field.
Yeah. And probably very nice to have some of that more detail with the free text responses rather than just checking boxes.
Yes. Yes.
And so I think this was a really wonderful study. Presumably, with it being a survey that there may be a little bit of of survey bias, but I think it does really help bridge some of that gap that I have a lot of patients that feel almost like it's gaslit when they're told that their myositis shouldn't be painful and they're experience experiencing pain.
Exactly, yes. We hear that a lot from the patients. They say that they do not feel like their pain is well understood by their care team. And hopefully this study again takes this question from how common is it to what kind of pain these patients are experiencing. And hopefully we have some other posters also at this ACR trying to understand what's driving this pain.
Is it more of a fibromyalgia like, nosoplastic pain? Is it more of a mechanical pain? Or is it inflammation driven pain? So once we understand the mechanisms better, hopefully we will be able to develop specific treatment management strategies for these patients. Thank
you very much. Appreciate you educating us on this topic. And for more information on ACR convergence coverage, tune in to RheumNow for more.
Thank you. Thank you for having me.
Thank you.
Go to rheumnow.live to see the full program and register today.
Hello. I'm Anthony Chan reporting for RheumNow here at ACR twenty six in Orlando. And one of the areas that have been studied quite a lot in this meeting is the whole area of nosyplastic pain, where the pain can be coming from conditions such as fibromyalgia, particularly in the area of XBA. And today, there was a nice abstract one three three seven, which was presented here. And I'm together with, Mohamed Bitta from Oregon who actually was presenting this today.
So, Mohamed, very nice welcome to, the room now.
Thank you so much for having me.
Tell us a little bit about this study which you presented today where you assessed nocciplastic pain in EXPA.
Definitely, thank you. So one of the biggest challenges of Axospondyloarthritis is how to phenotype pain. You know, we have different phenotypes, nociceptive which is stemming from active inflammation, neuropathic and nocciplastic. Nocciplastic tend to be the trickiest part because there's pain coming from altered CNS processing and we cannot identify active inflammation or a threat to the tissue. And this is of course the prototype of it is fibromyalgia, but this is very common in patients with exospondyloarthritis up to fifty percent in some studies they end up having nociclastic pain features.
The answer is not to cycle biologics or further intensify the immune system. The answer is to try to quantify, objectify this nociclastic pain and to target that in order to modulate pain and to get patients to a better outcome. So what we did in this study, first we tried to phenotype pain, we get patients, we then do questionnaires, fibromyalgia survey questionnaires ask us, we also try to look at objective evidence of inflammation by doing sacroiliac joint MRIs, by doing CRP levels, and then these patients will undergo what we call quantitative sensory testing. As you know now in the clinic we ask patients rate on a scale from zero to 10 your pain scale. This is very non specific, I personally do not know how to answer this question.
What we're trying to do from this quantitative sensory testing is to try to get an objective number that can maybe help differentiate between different pain phenotypes. So we did three different techniques, one is pressure thresholds. Using an algo meter we apply pressure to specific points in the body, whether it's a joint or it's a non joint area, and whenever patients start feeling pain it will give us a threshold, it's a number. And we are doing other types of techniques such as temporal summation, when we have a neuropen we do repetitive pricks on the trapezius muscle which is a non articular site also to see at the end of that test what would be the number. We think that this is much more objective than asking a scale from zero to 10 and the very interesting finding that we have is that these quantitative sensory testing in specific the pressure thresholds was able to differentiate between patients who have nociplastic pain features versus not and how we define that, we define that based on a cutoff on the fibromyalgia survey questionnaire, because if you're starting with this patient population that we phenotyped nicely, they do not have active inflammation on MRIs or lab work, and then you're having a score that's giving them like widespread pain symptoms and then correlated very nicely with pressure thresholds on the quantitative sensory testing, this reflects the pain phenotype that we're trying to study and we are hoping that we can probably implement this in the future if possible to be able to measure pain in a more objective way.
If we can prove in the future that by employing these type of quantitative sensory testing early on in the patient journey, maybe we might be able to predict who will develop what type of pain and then we can target their pain based on that. Of course there's a lot more things to do but we're starting with the first step right
now. Thanks very much, that seems a very comprehensive study that you presented. Are there people who can have both? Can they be nociceptive and nociceptive at the same time? In other words, these tests can be positive but the MRI can also be positive.
Definitely, this is a very important question and yes, we can have patients who have both phenotypes, nociceptive and nociceptive. Of course, the beginning, at this point in time in 2026, it's not possible really to know which one is the predominant phenotype until we target the inflammation. Our approach is first we target the inflammatory component after some period of time, usually up to six months, where we give the anti inflammatory medication a good amount of time to work, at that point we reassess. If we are seeing any active inflammation, we cannot label it as nociceptive because we might still have nociceptive. But if the nociceptive component is gone, at that point we are more confident that we are dealing with nociceplastic pain features.
Okay, very nice. So I think the message is that it's possible to have one or both in these patients and these tools will help us to classify them a bit better.
Definitely, that's correct.
So thank you very much for that very nice abstract today. I'm Anthony Chan presenting here for RheumNow in Orlando at ACR twenty twenty
six. Thank you.
Hello, and welcome to ACR convergence coverage here on RheumNow. I'm Eric Dine from Summit, New Jersey. I'm joined by doctor Sagan from from Rush, myositis division. And I'm here today to talk to you about abstract 2825. Tell me a little bit about your study.
So again, I'm Deidam Sagan. I'm a myositis clinician researcher from Rush. And in the study, we have conducted an electronic survey, cross sectional survey study, where patients with myositis, about five fifty two patients with myositis who report pain attributable to myositis responded to the survey, and our goal was to understand the characteristics of pain in these patients. So pain was just thought to be not actually prominent in myositis. It's just the, it was long believed to be a painless disease.
So this is really, I guess, taking that step forward, like saying that this is common and now we're trying to understand the characteristics of pain in these people.
And so when you're studying for the boards, usually will say painless disorder. How many of these patients did you find have pain?
Yes. So in several different studies that we've done, approximately seventy percent of patients with myositis report pain that's significant enough to interfere with their daily activities. In some cohort, this number goes up to eighty six percent, and in some of them, it is lower, about sixty five percent, but in general, it seems like majority of the patients with myositis report pain.
And so tell me about how did you find the patients for the study and how did you ask them questions?
Yeah, so this was an electronic survey and we've collaborated with two patient organizations to distribute the survey. And one was the TMA, the Myositis Association, that's the largest patient organization, as well as the MSU, the Myositis Support and Understanding Group. They have their listservs, they have several social media platforms that they actively use, and they've advertised and circulated our survey on these platforms.
And were you able to get a little bit more information about the type of pain, how they describe this pain in Yes,
yes. So that was our goal. So we asked the patients, you know, first of all, we said, do you feel this more in the morning, more in the evening? How does it change during the day? We saw that that was quite variable, and some people reported being worse in the morning, some in the evening, some it's about the same.
So that was one diurnal variation that we've asked people. And then also we asked people, you know, is this a pain that kind of comes and goes or is it a persistent? And majority, over seventy percent of patients said this is a persistent pain that's there all the time.
Was there a difference between myositis subgroups?
Yeah, that is a good question because, so overlap myositis, the patients with myositis who also meets criteria for other autoimmune diseases had the highest levels of pain, and patients with inclusion body myositis had the lowest levels of pain. One
of the things I found interesting about your study was that you had not just, you had quantitative and qualitative information and patients were able to provide you really detailed information. Tell me a little bit about how you're able to understand that qualitative information.
Yeah, so we had two questions in the survey where we asked the patients with a free text question, how do you know that this pain is coming from your myositis and not from something else? So that was one free text question because we really did not wanna give them choices and bias them in any way. It's a new concept and we wanted to learn as much as we can. And then the other question we asked was what makes your pain better and what makes your pain worse in your opinion? So the way we analyze this data, initially, we really didn't expect to get this many responses to our survey.
So we were gonna do a qualitative analysis. But given that we had over 500 responses and all of them had the answers to this free text question, We use actually large language models, the CHECH GPT, and we ask to create themes as well as representative quotes from each theme as an answer to that question. So this is an exploratory approach, obviously, but I think it's gonna be developed and used more and more commonly in the rheumatology field.
Yeah. And probably very nice to have some of that more detail with the free text responses rather than just checking boxes.
Yes. Yes.
And so I think this was a really wonderful study. Presumably, with it being a survey that there may be a little bit of of survey bias, but I think it does really help bridge some of that gap that I have a lot of patients that feel almost like it's gaslit when they're told that their myositis shouldn't be painful and they're experience experiencing pain.
Exactly, yes. We hear that a lot from the patients. They say that they do not feel like their pain is well understood by their care team. And hopefully this study again takes this question from how common is it to what kind of pain these patients are experiencing. And hopefully we have some other posters also at this ACR trying to understand what's driving this pain.
Is it more of a fibromyalgia like, nosoplastic pain? Is it more of a mechanical pain? Or is it inflammation driven pain? So once we understand the mechanisms better, hopefully we will be able to develop specific treatment management strategies for these patients. Thank
you very much. Appreciate you educating us on this topic. And for more information on ACR convergence coverage, tune in to RheumNow for more.
Thank you. Thank you for having me.
Thank you.

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.